NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

Restricted access

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Provided content development and/or authorship assistance.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel's discussion, including the literature reviewed.

The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines is available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:730.

  • 2.

    Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January 24, 2018.

    • Search Google Scholar
    • Export Citation
  • 3.

    Amin MB, Edge SB, Greene F, eds. AJCC Cancer Staging Manual, 8th ed. New York, NY: Springer International Publishing; 2017.

  • 4.

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

  • 5.

    von der Maase H, Sengelov L, Roberts JT. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:46024608.

    • Search Google Scholar
    • Export Citation
  • 6.

    Tarin TV, Power NE, Ehdaie B. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol 2012;61:10251030.

    • Search Google Scholar
    • Export Citation
  • 7.

    Stein JP, Lieskovsky G, Cote R. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666675.

    • Search Google Scholar
    • Export Citation
  • 8.

    Ghoneim MA, Abdel-Latif M, el-Mekresh M. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008;180:121127.

    • Search Google Scholar
    • Export Citation
  • 9.

    Bajorin DF, Dodd PM, Mazumdar M. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:31733181.

    • Search Google Scholar
    • Export Citation
  • 10.

    Meijer RP, Mertens LS, van Rhijn BW. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 2014;83:134139.

  • 11.

    Azuma H, Inamoto T, Takahara K. The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis. Int J Oncol 2014;44:18951903.

    • Search Google Scholar
    • Export Citation
  • 12.

    Stanik M, Poprach A, Macik D. Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery. Neoplasma 2018;65:287291.

    • Search Google Scholar
    • Export Citation
  • 13.

    Zargar-Shoshtari K, Zargar H, Lotan Y. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol 2016;195:5359.

    • Search Google Scholar
    • Export Citation
  • 14.

    Grossman HB, Natale RB, Tangen CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 15.

    Sternberg CN, de Mulder PH, Schornagel JH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 2001;19:26382646.

    • Search Google Scholar
    • Export Citation
  • 16.

    von der Maase H, Hansen SW, Roberts JT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:30683077.

    • Search Google Scholar
    • Export Citation
  • 17.

    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Eur Urol 2005;48:202205; discussion 205–206.

    • Search Google Scholar
    • Export Citation
  • 18.

    Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189199; discussion 199–201.

    • Search Google Scholar
    • Export Citation
  • 19.

    Zaghloul MS, Awwad HK, Akoush HH. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys 1992;23:511517.

    • Search Google Scholar
    • Export Citation
  • 20.

    Shipley WU, Winter KA, Kaufman DS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 21.

    Efstathiou JA, Spiegel DY, Shipley WU. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705711.

    • Search Google Scholar
    • Export Citation
  • 22.

    Kaufman DS, Winter KA, Shipley WU. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471476.

    • Search Google Scholar
    • Export Citation
  • 23.

    Hagan MP, Winter KA, Kaufman DS. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665672.

    • Search Google Scholar
    • Export Citation
  • 24.

    Kaufman DS, Winter KA, Shipley WU. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73:833837.

    • Search Google Scholar
    • Export Citation
  • 25.

    Mitin T, Hunt D, Shipley WU. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 2013;14:863872.

    • Search Google Scholar
    • Export Citation
  • 26.

    Coppin CM, Gospodarowicz MK, James K. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:29012907.

    • Search Google Scholar
    • Export Citation
  • 27.

    Housset M, Maulard C, Chretien Y. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:21502157.

    • Search Google Scholar
    • Export Citation
  • 28.

    James ND, Hussain SA, Hall E. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:14771488.

  • 29.

    Mak RH, Zietman AL, Heney NM. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008;102:13451353.

  • 30.

    Rodel C, Grabenbauer GG, Kuhn R. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:30613071.

    • Search Google Scholar
    • Export Citation
  • 31.

    Shipley WU, Kaufman DS, Zehr E. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:6267; discussion 67–68.

    • Search Google Scholar
    • Export Citation
  • 32.

    Haque W, Verma V, Butler EB, Teh BS. Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the National Cancer Data Base. Bladder Cancer 2017;3:283291.

    • Search Google Scholar
    • Export Citation
  • 33.

    Hermans TJ, Fransen van de Putte EE, Horenblas S. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—results of a nationwide population-based study. Eur J Cancer 2016;69:18.

    • Search Google Scholar
    • Export Citation
  • 34.

    De Santis M, Bellmunt J, Mead G. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191199.

    • Search Google Scholar
    • Export Citation
  • 35.

    Bellmunt J, Theodore C, Demkov T. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:44544461.

    • Search Google Scholar
    • Export Citation
  • 36.

    Kaufman D, Raghavan D, Carducci M. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:19211927.

    • Search Google Scholar
    • Export Citation
  • 37.

    Sternberg CN, de Mulder P, Schornagel JH. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:5054.

    • Search Google Scholar
    • Export Citation
  • 38.

    De Santis M, Bellmunt J, Mead G. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol 2009;27:56345639.

    • Search Google Scholar
    • Export Citation
  • 39.

    Balar AV, Galsky MD, Rosenberg JE. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:6776.

    • Search Google Scholar
    • Export Citation
  • 40.

    Balar AV, Castellano D, O'Donnell PH. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:14831492.

    • Search Google Scholar
    • Export Citation
  • 41.

    US Food & Drug Administration. FDA Alerts Health Care Professionals and Oncology Clinical Investigators About an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer With Low Expression of PD-L1. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm. Updated June 20, 2018. Accessed June 27, 2018.

    • Search Google Scholar
    • Export Citation
  • 42.

    Bellmunt J, de Wit R, Vaughn DJ. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:10151026.

  • 43.

    Rosenberg JE, Hoffman-Censits J, Powles T. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:19091920.

    • Search Google Scholar
    • Export Citation
  • 44.

    Powles T, Duran I, van der Heijden MS. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748757.

    • Search Google Scholar
    • Export Citation
  • 45.

    Sharma P, Retz M, Siefker-Radtke A. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312322.

    • Search Google Scholar
    • Export Citation
  • 46.

    Sharma P, Callahan MK, Bono P. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17:15901598.

    • Search Google Scholar
    • Export Citation
  • 47.

    Massard C, Gordon MS, Sharma S. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34:31193125.

    • Search Google Scholar
    • Export Citation
  • 48.

    Powles T, O'Donnell PH, Massard C. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3:e172411.

    • Search Google Scholar
    • Export Citation
  • 49.

    Apolo AB, Infante JR, Balmanoukian A. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 2017;35:21172124.

    • Search Google Scholar
    • Export Citation
  • 50.

    Patel MR, Ellerton J, Infante JR. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:5164.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 4 0 0
Full Text Views 4498 3101 169
PDF Downloads 1276 883 85
EPUB Downloads 0 0 0